Article

Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain West

2025-10-02

Abstract excerpt

<h4>ABSTRACT</h4> <h4>INTRODUCTION</h4> Lecanemab is a monoclonal antibody targeting amyloid plaques that has been approved for the treatment of Alzheimer’s disease. Here, we report on the clinical history and outcomes of the first 70 patients at the University of Utah to receive amyloid-removal therapy. <h4>METHODS</h4> This is a retrospective analysis of patients treated with lecanemab over a 26-month period....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 37c17479-f68b-5135-9a65-fd3231d6181d
DOI: 10.1101/2025.09.30.25337002

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain WestDOI 10.1101/2025.09.30.25337002Read

Real-World Characterization of Amyloid-Related Imaging Abnormalities (ARIA) in Lecanemab Treatment at an Academic Health SystemSemantic proximity Read

Fatal Iatrogenic Cerebral Amyloid-Related Encephalitis in a patient treated with lecanemab for Alzheimer’s disease: neuroimaging and neuropathologySemantic proximity Read

Fatal Iatrogenic Cerebral Amyloid-Related Encephalitis in a patient treated with lecanemab for Alzheimer’s disease: neuroimaging and neuropathology.Semantic proximity Read

Patient attitude towards lecanemab: results from a survey within the European Alzheimer’s disease consortium (EADC), the German memory clinic network (DNG) and Austrian memory centersSemantic proximity Read

Reducing ARIA risk in Alzheimer's disease: Real-world impact of APOE genotype-guided slow titration with aducanumab and lecanemab.Semantic proximity Read

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?Semantic proximity Read

Are Pre-frail and Frail Amyloid Positive Individuals Eligible to Lecanemab? A cross-sectional analysis from the Cogfrail Real-World CohortSemantic proximity Read

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationSemantic proximity Read

Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brainSemantic proximity Read

Lecanemab and APOE Genotyping in Clinical Practice-Navigating Uncharted Terrain.Semantic proximity Read

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialSemantic proximity Read

Geographic variation in dementia-related adverse events associated with sacubitril/valsartan: Analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read